Consenso sobre lipoproteína (a) de la Sociedad Española de Arteriosclerosis.: Revisión bibliográfica y recomendaciones para la práctica clínica

Identificador:  imarina:9441709

Handle: https://hdl.handle.net/20.500.11797/imarina9441709

Autors:  Francisco Javier Delgado Lista; José M Mostaza; Teresa Arrobas Velilla; Francisco Blanco Vaca; Lluís Masana Marín; Juan Pedro Botet; Pablo Pérez Martínez; Fernando Civeira Murillo; José Ignacio Cuende Melero; José Javier Gómez Barrado; Carlos Lahoz Rallo; Xavier Pintó Sala; Manuel A Suárez Tembra; José López Miranda; Carlos Guijarro Herráiz

Resum:
The irruption of lipoprotein(a) (Lp(a)) in the study of cardiovascular risk factors is perhaps, together with the discovery and use of proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor drugs, the greatest novelty in the field for decades. Lp(a) concentration (especially very high levels) has an undeniable association with certain cardiovascular complications, such as atherosclerotic vascular disease (AVD) and aortic stenosis. However, there are several current limitations to both establishing epidemiological associations and specific pharmacological treatment. Firstly, the measurement of Lp(a) is highly dependent on the test used, mainly because of the characteristics of the molecule. Secondly, Lp(a) concentration is more than 80% genetically determined, so that, unlike other cardiovascular risk factors, it cannot be regulated by lifestyle changes. Finally, although there are many promising clinical trials with specific drugs to reduce Lp(a), currently only iPCSK9 (limited for use because of its cost) significantly reduces Lp(a). However, and in line with other scientific societies, the SEA considers that, with the aim of increasing knowledge about the contribution of Lp(a) to cardiovascular risk, it is relevant to produce a document containing the current status of the subject, recommendations for the control of global cardiovascular risk in people with elevated Lp(a) and recommendations on the therapeutic approach to patients with elevated Lp(a).